ACET Stock Analysis: Buy, Sell, or Hold?
ACET - Adicet Bio, Inc. Common Stock
$9.16
-0.05 (-0.54%)
▼
5d:
+10.36%
30d:
+6.51%
90d:
+7.64%
BUY
MODERATE Confidence
Analysis Updated: Aug 5, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When ACET Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ACET shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ACET shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ACET is currently trading at $9.16, which is considered extended relative to its 30-day fair value range of $8.20 to $9.06.
Technical Outlook: Technically, ACET is in a strong uptrend. Immediate support is located at $7.74, while resistance sits at $9.84.
Market Sentiment: ACET has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (14th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $34.83 (+280.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ACET is in a strong uptrend. Immediate support is located at $7.74, while resistance sits at $9.84.
Market Sentiment: ACET has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (14th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $34.83 (+280.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$8.20 -
$9.06
Company Quality Score
52/100
(HOLD)
Options IV Signal
14th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
70.8%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 14th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 280.3% below Wall St target ($34.83)
Trading Range Analysis
30-Day Trading Range
$8.20 -
$9.06
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$1.36
(14.8%)
Support & Resistance Levels
Support Level
$7.74
Resistance Level
$9.84
Current Trend
Strong Uptrend
Technical data as of
Aug 5, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.63
Wall Street Target
$34.83
(+280.3%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: August 05, 2026 8:01 PM ET
Data refreshes hourly during market hours. Next update: 9:01 PM
Data refreshes hourly during market hours. Next update: 9:01 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACET showing a specific setup today?
Insider Activity (6 Months)
3
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Ra Capital Management, L…
BUY
74751 shares
2026-02-20
Ra Capital Management, L…
BUY
74268 shares
2026-02-19
Ra Capital Management, L…
BUY
74577 shares
2026-02-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 55 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 57 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$282 | 57 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$105 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$33 | 53 HOLD |
